The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

BACKGROUND Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor. OBJECTIVE Our aim was to evaluate the efficacy of the type 1 and 2 5alpha-reductase inhibitor dutasteride in men with MPHL. METHODS Four hundred sixteen men, 21 to 45 years old, were randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily for 24 weeks. RESULTS Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. Expert panel photographic review and investigator assessment of hair growth confirmed these results. Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a dose-dependent fashion with dutasteride. LIMITATIONS The study was limited to 24 weeks. CONCLUSION Dutasteride increases scalp hair growth in men with MPHL. Type 1 and type 2 5alpha-reductase may be important in the pathogenesis and treatment of MPHL.

[1]  J. Imperato-McGinley,et al.  Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. , 1999, Journal of the American Academy of Dermatology.

[2]  J. Waldstreicher,et al.  The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. , 1999, Journal of the American Academy of Dermatology.

[3]  N. Sadick,et al.  The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. , 1994, The Journal of clinical endocrinology and metabolism.

[4]  J. Shapiro,et al.  Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. , 1998, Journal of the American Academy of Dermatology.

[5]  Harris,et al.  Immunohistochemical localization of types 1 and 2 5α‐reductase in human scalp , 1999, The British journal of dermatology.

[6]  D. Canfield.  Photographic documentation of hair growth in androgenetic alopecia. , 1996, Dermatologic clinics.

[7]  D. Thiboutot,et al.  Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. , 1999, British Journal of Dermatology.

[8]  D. Russell,et al.  Steroid 5α-Reductase 2 Deficiency , 1993 .

[9]  M. Sawaya,et al.  Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. , 1997, The Journal of investigative dermatology.

[10]  Rodney D Sinclair.  Male pattern androgenetic alopecia , 1998, BMJ.

[11]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[12]  Bhushan Kumar,et al.  Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. , 2003, Archives of dermatology.

[13]  C. Roehrborn,et al.  Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia , 2004 .

[14]  M. Koronkowski,et al.  Finasteride: The First 5α‐Reductase Inhibitor , 1993 .

[15]  E. Olsen.  Disorders of hair growth : diagnosis and treatment , 1994 .

[16]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  D. Thiboutot,et al.  Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. , 1995, The Journal of investigative dermatology.

[18]  M. K. James,et al.  Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  O. Norwood,et al.  Male Pattern Baldness: classification and Incidence , 1975, Southern medical journal.

[20]  B. Bernard,et al.  Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit. , 1996, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[21]  Takayasu,et al.  Predominance of type I 5α‐reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis) , 1998, The British journal of dermatology.

[22]  P. Vilja,et al.  Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  D. Whiting.  Male pattern hair loss: current understanding , 1998, International journal of dermatology.

[24]  J. D. Wilson,et al.  Steroid 5 alpha-reductase: two genes/two enzymes. , 1994, Annual review of biochemistry.

[25]  D. Hermann,et al.  EFFECTIVE SUPPRESSION OF DIHYDROTESTOSTERONE (DHT) BY GI198745, A NOVEL, DUAL 5 ALPHA REDUCTASE INHIBITOR , 1999 .